Capital International Investors’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Capital International Investors’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-675,371	Closed	-$2.76M	–	460
2024 Q2	$2.76M	Sell	675,371 -2,144,293	-76%	-$23.9M	﹤0.01%	418
2024 Q1	$44.4M	Hold	2,819,664	–	–	0.01%	332
2023 Q4	$42.7M	Sell	2,819,664 -308,094	-10%	-$4.49M	0.01%	337
2023 Q3	$62.7M	Hold	3,127,758	–	–	0.02%	308
2023 Q2	$88.2M	Hold	3,127,758	–	–	0.02%	297
2023 Q1	$53.8M	Buy	3,127,758 +79,576	+3%	+$1.61M	0.01%	327
2022 Q4	$61.4M	Buy	+3,048,182	New	+$65.6M	0.02%	317

Other funds holding ZNTL

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Capital International Investors's ZNTL Position: Q3 2024 in Review

Capital International Investors sold out of Zentalis Pharmaceuticals (ZNTL) in Q3 2024, closing a stake of 675,371 shares — an estimated $2.76M sold.

Capital International Investors first reported a position in ZNTL in Q4 2022 and held it in 7 quarters. The position peaked at $88.2M in Q2 2023. 136 funds tracked by Wall St. Rank hold ZNTL as of Q3 2024.

Capital International Investors reported no remaining Zentalis Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
Capital International Investors sold 675,371 Zentalis Pharmaceuticals shares in Q3 2024, an estimated $2.76M.
Capital International Investors first reported a position in Zentalis Pharmaceuticals in Q4 2022 and held it in 7 quarters.
Capital International Investors's Zentalis Pharmaceuticals position peaked at $88.2M in Q2 2023.
136 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q3 2024.

Based on Capital International Investors's 13F filing for Q3 2024, filed 13 Nov 2024.